Showing 1 - 10 of 42
Persistent link: https://www.econbiz.de/10001565125
Persistent link: https://www.econbiz.de/10009357376
Persistent link: https://www.econbiz.de/10003871705
Persistent link: https://www.econbiz.de/10011974969
Persistent link: https://www.econbiz.de/10011746831
Consumer cooperatives constitute a highly successful example of democratic forms of enterprises operating in developed countries. They are usually organized as medium and large-scale firms competing with pro fit-maximizing firms in retail industries. This paper models such situation as a mixed...
Persistent link: https://www.econbiz.de/10013132234
This paper proposes a formulation of coalitional payoff possibilities in games with externalities, based on the assumption that forming coalitions can exploit a first mover advantage. We derive a characteristic function and show that when outside players play their best response...
Persistent link: https://www.econbiz.de/10014128533
This paper examines a homogeneous-good Bertrand-Edgeworth oligopoly model to explore the role of firm size and number in pricing. We consider the price impact of merger, break up, investment, divestment, entry and exit. A merger leads to higher prices only when it increases the size of the...
Persistent link: https://www.econbiz.de/10014420154
We study the impact of regulatory regimes on generic competition and pharmaceutical pricing using a unique policy experiment in Norway, where reference pricing (RP) replaced price cap regulation in 2003 for a sub-sample of off-patent products. We exploit a detailed panel dataset at product level...
Persistent link: https://www.econbiz.de/10014198115
Policy makers use reference pricing to curb pharmaceutical expenditures by reducing coverage of expensive branded drugs. In a theoretical analysis we show that the net effect of reference pricing is generally ambiguous when accounting for entry by generic producers. Reference pricing shifts...
Persistent link: https://www.econbiz.de/10014080046